雷公藤多苷和厄贝沙坦治疗2型糖尿病肾病的效果观察

The Effect Observation of Treating II Diabetic Nepbropathy with Tripterygium Glycosides Combined Irbesartan

目的:讨论雷公藤多苷和厄贝沙坦治疗2型糖尿病肾病的效果。方法:随机选取并回顾性分析自2012-02～2012-06月就诊的2型糖尿病患者85例。研究组45例患者采用厄贝沙坦联合雷公藤多苷治疗,对照组40例患者,单用厄贝沙坦。比较两组患者尿蛋白、血红蛋白、血脂以及糖尿病肾病等相关指标。结果:两组患者尿蛋白、血红蛋白、TC、TG、LDL、HDL、均存在明显统计学差异(P<0.05),且对研究组各项指标均优于对照组。24周后研究组患者治疗无效率9例(20%),对照组患者治疗无效率19例(47.5%)。结论:雷公藤多苷和厄贝沙坦联合使用能够控制患者血红蛋白、尿蛋白及血脂水平,延缓2型糖尿病患者肾损害,提高疗效,值得临床推广。

Objective：To discuss the effect of treating II diabetic nepbropathy with tripterygium glycosides combined irbesartan. Methods：Choosed 85 patients of II diabetic nepbropathy from Feb. 2012 to Jun. 2012 to divide into study group and controlled group. Study group with 45 cases were treated with tripterygium glycosides combined irbesartan, and controlled group were treated with irbesartan only. Compared the index of urinary protein, hemoglobin, blood - lipid. Results： There was different in urinary protein, hemoglobin, blood - lipid between these two groups （ P 〈 0. 05 ）,And there were 9 cases invalid （20%） in study group, and 19 cases invalid in controlled group （47. 5% ）. Conclusions： Treating II diabetic nepbropathy with tripterygium glycosides combined irbesartan has good effect to extend in clinic.